Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CBRS17061 / EA1131 / Michelle Shayne

Research Question:
What are the good and bad effects of getting more treatment with capecitabine (i.e. one of the usual approaches) compared to getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin) after surgery?

Basic Study Information

Purpose:
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

Location: University of Rochester Medical Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02445391?term=ea1131&rank=1
Study Reference #: CBRS17061

Lead Researcher (Principal Investigator)

Lead Researcher:  Michelle Shayne, MD

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Breast Cancer

Return to Search